Fisher Wallace Laboratories Inc.

Prescription Wearables For Mental Health

Fisher Wallace Laboratories Inc.

Prescription Wearables For Mental Health

Brooklyn, NY
Health Tech
Fisher Wallace manufactures and markets prescription-only brain stimulation wearables that have been cleared by the FDA to treat depression, anxiety, and insomnia. The technology comfortably stimulates the brain to produce serotonin, lower cortisol, and modulate brain activity. The company is VC-backed and led by CEO Kelly Roman, who has helped pioneer the category since 2009.

$200,464

raised
$6,923,978
previously crowdfunded
157
Investors
$81.2M
Valuation
$8.81
Price per Share
$193.82
Min. Investment
Common
Shares Offered
Equity
Offering Type
$1M
Offering Max
17
Days Left

$200,464

raised
$6,923,978
previously crowdfunded
157
Investors
$81.2M
Valuation
$8.81
Price per Share
$193.82
Min. Investment
Common
Shares Offered
Equity
Offering Type
$1M
Offering Max
17
Days Left

Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!

Rewards

Get rewarded for investing more into Fisher Wallace Laboratories Inc.:

$193+
Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
$1,500+
Investment
Tier 1
Invest $1,500 and receive 2% bonus shares + a free device.
$5,000+
Investment
Tier 2
Invest $5,000 and receive 5% bonus shares + a free device.
$10,000+
Investment
Tier 3
Invest $10,000 and receive 10% bonus shares + a free device.
$25,000+
Investment
Tier 4
Invest $25,000 and receive 15% bonus shares + a free device + a 30-minute zoom with our CEO.

Reasons to Invest


  • Over $30 million in lifetime revenue and over 14,000 prescribers; OAK (Version 2) designed by Eric Fields (Beats, Nest) and engineered by Alloy Product Development (Beats, Microsoft) for release in 2023.


  • Currently FDA-Cleared and pursuing new FDA-Approval for the treatment of Major Depressive Disorder and new FDA-Clearance for Generalized Anxiety Disorder and Insomnia.


  • $6.85 million raised previously on StartEngine, and $2.75 million raised from VC firm SHUFL Capital. 


*OAK (Version 2) is currently under development and not yet available on the market.

Overview


Meet Fisher Wallace: developing a new standard of care

*OAK (Version 2) is currently under development and not yet available on the market.


Fisher Wallace has developed a wearable medical device that electrically stimulates the brain to improve mental health without causing serious side effects. The company’s proof-of-concept device, the Fisher Wallace Stimulator®, has been cleared by the FDA to treat depression, anxiety and insomnia and has been purchased by over 85,000 patients.


In 2021, the company submitted research conducted during the pandemic to the FDA, and is awaiting the agency's decision on new treatment indications. In early 2022, the company launched a pivotal clinical trial to obtain FDA approval for the treatment of Major Depressive Disorder. The FDA is expected to render a decision on this new data by early 2023. 


In a pilot study conducted at Mount Sinai Beth Israel Hospital in 2015, subjects who used an active Fisher Wallace device experienced durable depression relief, while subjects who used a placebo device returned to baseline. Over 14,000 providers have prescribed the device since 2009.


The company is nearing completion of its Version 2 device, called OAK, which features industrial design from Eric Fields - the award-winning designer of the Nest thermostat and the Beats pill. The company’s engineering partner, Alloy Product Development, previously engineered the Microsoft HoloLens. 

thE Market


The US spends over $225 billion a year on mental health treatment

Source: NAMI



Depression and anxiety affect one in three Americans (source and source), and at least 50 million Americans suffer from a sleep disorder (source). Recent data shows that the pandemic accelerated antidepressant use, with 23% more Americans taking an antidepressant in the third quarter of 2020-2021 versus the same quarter in 2015-2016. (source)

The problem


Side effects, modest efficacy, and high cost make drug therapy and behavioral therapy insufficient solutions


Medication for depression, anxiety and insomnia causes a wide range of side effects, sometimes serious, and even in generic form is expensive when the cost of doctor visits is included. The average cost of seeing a therapist is $100 - $200 per session (source) and as many as half of all patients fail to complete the “homework” associated with cognitive behavioral therapy that’s needed to experience results (source). While these standards of care help millions of patients every year, millions more are in need of safe, effective alternatives or adjuncts.


the solution


Rapid, affordable treatment with minimal side effects


Patients use the company’s technology at home for 20 minutes, once or twice a day. The company provides a free prescription process during e-commerce checkout and a 30-day, full refund policy. In a recent customer survey, 76.5% of Fisher Wallace customers stated that they intend to use the device for the rest of their lives to maintain mental health and cognitive performance, and 26.9% stated that the device is more important than their cell phone.


*OAK (Version 2) is currently under development and not yet available on the market.

our traction


Proven product-market fit and scalability



By leveraging a vertically integrated e-commerce model, Fisher Wallace has succeeded in generating over $30 million in net revenue.


The Seattle Police Department launched a pilot program with the Fisher Wallace device in January 2022. Fisher Wallace intends to scale its solution to additional police departments and first responder communities nationally.


Medicaid in Maine (MaineCare) became the first state Medicaid program to fully cover the purchase of the Fisher Wallace device. Ongoing clinical research is designed to both obtain new FDA Approval and Clearances, as well as enable the company to expand insurance coverage. 


We plan to release OAK (Version 2) in 2023 and will offer it as a free perk to StartEngine investors who invest at least $1,500 - alternatively, these investors may choose to receive Version 1 for free (Version 1 perk device will be shipped after the close of the campaign).

*OAK (Version 2) is currently under development and not yet available on the market.

why invest


Join us as we reinvent mental health treatment

*OAK (Version 2) is currently under development and not yet available on the market.


With more than a decade of product development, clinical trial, regulatory, and marketing experience, and with over $30 million in lifetime revenue and $9.6 million in capital raised, our team is uniquely prepared to bring a refreshing vision of mental healthcare to life. We believe we possess the technology, experience, and timing required to successfully scale a new standard of care for those suffering from common mental health conditions. Become a shareholder in Fisher Wallace and help make mental health treatment better and more accessible for everyone. Invest $1500+ and receive the company’s Version 1.0 device (on market) or Version 2.0 device (available in 2023) for free!

Offering Summary


Company

:

Fisher Wallace Laboratories Inc.

Corporate Address

:

630 Flushing Avenue, Suite #104, Brooklyn, NY 11206

Offering Minimum

:

$9,999.35

Offering Maximum

:

$1,000,084.77

Minimum Investment Amount

(per investor)

:

$193.82











Terms


Offering Type

:

Equity

Security Name

:

Class B Non-Voting Common Stock

Minimum Number of Shares Offered

:

1,135

Maximum Number of Shares Offered

:

113,517

Price per Share

:

$8.81

Pre-Money Valuation

:

$81,236,322.82











*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.

Investment Incentives and Bonuses*

Loyalty Bonus, 5% Bonus Shares: As you have previously invested in Fisher Wallace, you are eligible for additional bonus shares.

Time-Based:

Super Early Bird Bonus

Invest within the first 72 hours and receive 10% bonus shares.

Early Bird Bonus

Invest within the first week and receive 5% bonus shares.

Amount-Based:

$1,500+ | Tier 1

Invest $1,500 and receive 2% bonus shares + a free device. 

$5,000+ | Tier 2

Invest $5,000 and receive 5% bonus shares + a free device.

$10,000+ | Tier 3

Invest $10,000 and receive 10% bonus shares + a free device.

$25,000+ | Tier 4

Invest $25,000 and receive 15% bonus shares + a free device + a 30-minute zoom with our CEO.

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus:

Fisher Wallace Laboratories Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Class B Non-Voting Common Stock at $8.81 / share, you will receive 110 shares Class B Non-Voting Common Stock, meaning you'll own 110 shares for $881. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus and the Loyalty Bonus in addition to the aforementioned bonus.

*Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Irregular Use of Proceeds

We will not incur any irregular use of proceeds.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$1,999,403.00 USD
$853,359.00 USD
Cash And Cash Equivalents
$1,929,380.00 USD
$695,749.00 USD
Accounts Receivable
$0.00 USD
$2,302.00 USD
Short Term Debt
$471,468.00 USD
$725,122.00 USD
Long Term Debt
$576,525.00 USD
$620,416.00 USD
Revenues And Sales
$4,230,290.00 USD
$4,250,866.00 USD
Costs Of Goods Sold
$623,703.00 USD
$970,761.00 USD
Taxes Paid
$250.00 USD
$1,597.00 USD
Net Income
-$3,262,291.00 USD
-$1,823,732.00 USD

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Updates

WE HAVE LIFETIME CUSTOMERS

3 hours ago

Dear Investors.

77.4% of our surveyed customers report that they intend to use our technology for the rest of their lives to maintain mental health and cognitive performance (see below). In short, the vast majority of our customers may in fact be lifetime customers. This is one of many reason why we are investing in building a Version 2 device. The app we intend to release next year will also offer talk therapy - for many patients, combinational therapy is the best way to treat depression and anxiety. The advantage Fisher Wallace will have over digital health companies that offer talk therapy (such as TalkSpace) is that we will have already acquired the customer through the hardware purchase. Talk therapy costs, on average, between $100 - $200 per session (citation) - so for patients who make healthcare decisions based on cost, our hardware alone is an extremely high-value, low-cost purchase. For customers who can afford talk therapy and want to pursue it, our app will be there to serve them. 

The fact that so many of our customers consider our device as important as their cell phone is also a testament to the value we deliver. 

We've recently engaged in price testing, and have seen a significant increase in conversions since we lowered our retail price to $299 - last month was our highest revenue month in history. Neither talk therapy nor drug therapy provide full refund policies, but we are able to because our effectiveness rate is so high (as we've been proving in clinical trials over the past 2 years). Less than 15% of our customer return their device for a refund.

If you invest $1500+ in our campaign, you will receive a unique coupon code (after the close of the campaign in 17 days from today) that allows you to checkout on FisherWallace.com with a Version 1 (available now) or Version 2 device (2023) for free. The telemedicine prescription process is also free during checkout. If you simply wish to obtain a device immediately to treat depression, anxiety and/or insomnia, you may do so today on FisherWallace.com - our devices ship within days of ordering, via free FedEx Express shipping.

Thank for your consideration - we hope you not only become an investor but also benefit from the technology itself!

Best regards, 

Kelly Roman

Co-founder & CEO

Fisher Wallace Labs


LISTEN TO OUR CEO ON THE VATOR NEWS PODCAST

11 hours ago

Dear Investors,

We invite you to listen to Fisher Wallace Labs co-founder and CEO Kelly Roman as he discusses mental healthcare and startup strategy with Steven Loeb, host of the Vator News Podcast - a leading podcast in the healthtech space. The interview took place last week and is now streaming.

Our "flash crowdfunding campaign" ends in less than 3 weeks, with capital going towards research and development of OAK - with a shot at becoming the first FDA-Approved wearable for depression. The FDA submission deadline is December 11 and our pivotal clinical trial is on schedule for a data lock in October. 

Invest $1500+ and receive a coupon code to obtain OAK in 2023 or our Version 1 device (Fisher Wallace Stimulator) immediately after the campaign closes - as a free perk.

Best regards,

Fisher Wallace Labs

OUR INSOMNIA TRIAL RESULTS

4 days ago


Insomnia research Fisher Wallace conducted during the pandemic in 2020

Sleep medication is considered efficacious if it increases total sleep time by 20 minutes. Fisher Wallace conducted its most recent insomnia study during the height of the pandemic in 2020, when patients were in lockdown. The device increased total sleep time in active device participants by 26 minutes per night on average, whereas participants using a placebo device experienced a decrease in total sleep time of 16 minutes (untreated sleep worsened during the pandemic) - a difference between active and placebo of 42 minutes. These results were submitted to the FDA in March 2021 to obtain FDA re-clearance for the treatment of insomnia.

Starting a Personal Sleep Study

Patients use the device nightly for 20 minutes before going to sleep and may use a sleep tracker (Fitbit, Apple Watch) to obtain quantifiable proof of effectiveness (if you don't have a sleep tracker, you may write down the time you wake up each morning, if you typically wake up before an alarm).

The device is cleared by the FDA to treat both anxiety and insomnia, and this is important for patients who need better quality sleep: reducing anxiety before attempting sleep will often reduce the time it takes to fall asleep. Sleep trackers will record this data as well.

We invite you to listen to a short podcast created by a journalist who shared the sleep tracking data she recorded during her 30-day trial of the Fisher Wallace device.

Bottom line: Patients need only give the device 1 - 2 weeks to dramatically improve sleep, and may return it for a full refund if it's not a game changer. Only 15% of our customers return their device.


Invest $1500+ to receive our Version 1 or Version 2 device for free.

The campaign will close in 21 days.

UNLOCKING THE BRAIN'S POTENTIAL

6 days ago

Unlocking The Brain's Potential

Your brain determines exactly how you feel and sleep - and its ability to rapidly change, electrochemically, is truly remarkable.

Since 2007, Fisher Wallace has been a medical device company that specializes in harnessing the brain's electrochemical system to eliminate the symptoms of depression, anxiety and insomnia.

Our FDA-Cleared technology works by comfortably stimulating the brain for 20 minutes per session to produce serotonin and other neurotransmitters required for healthy mood and sleep, while also lowering cortisol and modulating the center brain regions responsible for the sympathetic nervous system (the "fight or flight" response).

The majority of patients achieve significant symptom reduction or remission within the first two weeks of use - without experiencing side effects.


A Convenient Self-Care Routine

Patients use the device for 20 minutes after waking up, and again for 20 minutes before going to bed. You may engage in your regular morning and evening activities while using the device - whether that's having a cup of coffee or watching TV.

When you experience rapid results, starting and ending each day with a brain stimulation session quickly becomes an enjoyable routine.

40% of our customers also report improvements in focus, concentration and memory - another benefit of consistently stimulating the brain.76% of our customers report that they intend to use the device for the rest of their lives to maintain mental health and cognitive performance.


Trusted by First Responders

Our device is currently being used by the Seattle Police Department, including by 911 dispatchers, to improve mental health and wellbeing. More departments are joining the pilot program. Over the prior decade, we have supported thousands of US military veterans and their family members by treating the common symptoms of post traumatic stress. Customers may obtain our device today at the same discounted price that we apply to large institutions.


Multiple Clinical Trials

We've performed 6 clinical trials, including a safety study with pediatric patients, a study at Phoenix House (substance use patients), and a bipolar depression study conducted at Mount Sinai Beth Israel Hospital. With over 1000 participants in our trials and approximately 85,000+ devices sold to patients through 14,000 providers, our technology is established as a safe and effective treatment option.


Patients only keep the device if it works for them.

Talk therapy and drug therapy are not refundable, despite half of patients not finding relief. No mental health treatment works for 100% of patients, which is why offer a 30-day full refund policy, with free return shipping. Less than 15% of our customers return their device for a refund.

We prioritize affordability out-of-pocket, as few insurance providers cover mental health treatment devices. The purchase is FSA / HSA eligible. No-interest payment plans are also offered during checkout.

Fisher Wallace provides respectful, easy-to-reach customer service - available by phone, chat and email seven days a week from 10am - 10pm EST.


Reviewed by Elle Magazine

"But since I couldn't stop talking about my good mood and hypercharged focus, my friends stopped laughing and started asking if they could borrow it. I'm reluctant to let go of my stimulator, however."

- Nina Burleigh, ELLE Magazine


OAK will arrive in 2023

A collaboration between Fisher Wallace, Alloy Product Development (Beats, HoloLens) and Eric Fields (Beats, Nest), OAK uses a new design vocabulary intended to integrate brain stimulation technology into the lives of millions of people. 


Invest $1500+ to receive our Version 1 or Version 2 device for free.

The campaign will close in 23 days.

EARLY BIRD BONUS ENDS TOMORROW

7 days ago

Dear Investors,

The Early Bird Bonus 5% bonus shares) ends tomorrow, and may be stacked with other bonuses and perks.


"But since I couldn't stop talking about my good mood and hypercharged focus, my friends stopped laughing and started asking if they could borrow it. I'm reluctant to let go of my stimulator, however."

- Nina Burleigh, ELLE Magazine


Invest $1500+ to receive Version 1 or Version 2 for free.

Fisher Wallace Labs

LETTER FROM THE CEO

8 days ago


Dear Investor,

Any CEO running a for-profit healthcare business should feel a fundamental level of discomfort in profiting off people who are simply trying to heal themselves.

Given the small number and size of research grants available through the NIH, the vast majority of medical device startups must raise capital for R&D by selling shares to investors who expect a return on their investment.

If Fisher Wallace can succeed in obtaining broad insurance coverage - one of the goals of our current depression clinical trial - our device will become free to many patients, and the price we charge insurance companies will be a fraction of the cost of talk therapy or generic drug therapy (when doctor visits to monitor dosage are included) over the course of a year. If we can dramatically lower the cost of providing mental healthcare (and reduce the number of patients with mental health issues who, as a population, consume far more healthcare services than those who don’t), will that ultimately lower the cost of insurance? I certainly hope so - it should.

The NIH grant process has too long a timeline (relative to our FDA submission deadlines) and does not yield initial grants large enough to cover the costs of large scale clinical trials required to obtain FDA Approval. The millions of dollars needed to engineer and manufacture a world-class device like OAK is simply not available from the government. We therefore must continue raising capital from investors in order to do so.

Fisher Wallace is modestly profitable on device sales when R&D expenses are excluded - when only the cost of advertising, manufacturing and overhead is deducted. In 2023, we intend to release our first mobile app that will offer talk therapy, allowing us to build a recurring revenue business by offering additional services to our customers. In order to spend money on research and product development, we must raise it.

Our customers know our technology works, and they have become the backbone of our R&D financing through StartEngine by buying shares in Fisher Wallace. If we achieve our goals over the next 12 months - a depression trial that obtains FDA-Approval, the launch of OAK, and insurance coverage expansion - we will be in a position to lead the wearable brain stimulation market for years to come. I believe next year's products and services will ultimately appeal to tens of millions of users.

It’s challenging to align the incentives of a for-profit healthcare business with the needs of patients. I think Fisher Wallace is doing the best job it possibly can to ensure everyone wins.

Best regards,

Kelly Roman

Co-Founder & CEO

Fisher Wallace Labs


EARLY BIRD BONUS ENDING SOON

INVEST $1500+ FOR A FREE VERSION 1 OR VERSION 2 DEVICE

THIS IS A 30-DAY CAMPAIGN

FREE DEVICE WITH $1500+ INVESTMENT

10 days ago

FREE DEVICE WITH $1500+ INVESTMENT

STACK BONUSES TODAY!



Our OAK pre-order page (currently sold out): https://www.fisherwallace.com/pages/oak

Leave a comment with any questions -our CEO will respond within 48 hours.

Thanks for your consideration! Only 27 days remain and early bird bonuses end very soon!

EARLY BIRD BONUS ENDS IN 24 HOURS!

11 days ago

Dear Investors, 

Our "flash equity crowdfunding campaign" launched 2 days ago and is only live for 30 days. With 28 days left, our Super Early Bird Bonus ends tomorrow. Here's recap of the current perks / bonuses and when they expire:


  • Super Early Bird Bonus: 10% Bonus Shares, Ends 72 Hours After Launch, IN ADDITION to any other bonuses (ends tomorrow)


  • StartEngine Owner's Bonus: 10% Bonus Shares, IN ADDITION to any other bonuses (continuous)


  • $1500+ Investment: Free Version 1 device (ships after close of campaign) or Version 2 device (ships in 2023) IN ADDITION to any other bonuses (continuous)


  • $5000+ Investment: 5% Bonus Shares + Free Version 1 or Version 2 device, IN ADDITION to any other bonuses (continuous)


  • $10,000+ Investment: 10% Bonus Shares + Free Version 1 or Version 2 device, IN ADDITION to any other bonuses (continuous)


  • $25,000+ Investment: 15% Bonus Shares + Free Version 1 or Version 2 device + 30-minute Zoom with CEO, IN ADDITION to any other bonuses (continuous)


Thanks for your consideration!





BONUS SHARES THIS WEEK!

12 days ago

BONUS SHARES FOR INVESTING THIS WEEK, FOR RE-INVESTING AND FOR STARTENGINE'S OWN INVESTORS (BONUSES MAY BE COMBINED) 


INVEST $1500+ TO OBTAIN A DEVICE FOR FREE



Dear Investor,


Fisher Wallace has largely pioneered the prescription wearable category for mental health over the past decade.

Over the past few months, tech behemoths such as Apple and Amazon have continued to move more aggressively into healthcare - note Amazon's planned purchase of One Medical for $3.9 billion.

Fisher Wallace has been investing in clinical research and product development to establish market position and momentum in our category - market position and momentum in a new category is something that big tech companies can't create overnight regardless of resources, and tend to acquire.

As Jeff Bezos said about Amazon's acquisition of Ring several years ago: “To be clear, my view here is that we’re buying market position — not technology,” Bezos wrote in an email thread four months before the company acquired Ring. “And that market position and momentum is very valuable.”

There are currently no wearable devices that are fully FDA-Approved to treat depression. We are two months away from completing our pivotal depression trial that will be submitted to FDA to obtain approval for the treatment of moderate to severe Major Depressive Disorder.

If we obtain FDA-Approval, we have the option of launching OAK either a prescription device for depression or as a prescription-strength wellness device, while keeping our Version 1 device (Fisher Wallace Stimulator) on the market as a discounted prescription-only device that is designed to obtain full insurance coverage (so Version 1 can become free to patients). Obtaining insurance coverage is another reason why we are investing aggressively in clinical research.

We've been simultaneously investing in OAK product development for over a year, which has often cost more than $250K a month (between engineering, industrial design and firmware development). Developing a world-class wearable device - with the designers and engineers of Beats, Nest and the Microsoft HoloLens - takes time regardless of scale and we will complete engineering of the prototype this year and finally enter the manufacturing phase. Recent supply chain challenges - most notably for Bluetooth chips - has made new hardware development for startups extremely difficult, and we are lucky that our Version 1 device (Fisher Wallace Stimulator), which doesn't use Bluetooth, faces no supply chain challenges. As a result, we've been able to scale sales of Version 1 over the past few months (graph above). By the time we release OAK commercially (Summer 2023), the supply chain disruptions should be largely a thing of the past.

In short, we are moving aggressively to transform our business from a startup success into large enterprise - we believe OAK, with its appealing design and new FDA Approval / Clearances (should we obtain them), will be something that tens of millions of users could adopt.

There are great perks for early, repeat investors that start to go away after this week!

Best Regards,


Kelly RomanCo-Founder & CEO
Fisher Wallace Labs



Perks for early and repeat investors!

13 days ago

Dear Investor,

Our new equity crowdfunding campaign just launched, with perks for early investors and repeat investors. This short campaign closes in 30 days.

We raised nearly $7 million in our previous three campaigns on StartEngine to fund OAK product development and clinical research (to obtain new FDA Approval). VC firm SHUFL Capital has also invested a total of $2.75 million.

OAK is designed to make our technology appealing to tens of millions of potential users - a massive project that will wrap up the majority of the engineering this year.

Recent news: July was the highest grossing month in our history with $853K in net sales - this equates to a $10M+ annual run rate (ARR), a major milestone for any startup!

Thank you for your consideration!


Kelly Roman

Co-Founder & CEO
Fisher Wallace Labs

P.S. If you already reserved shares over the past month, please make sure to confirm your investment through the email you will receive from StartEngine today!


 

Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
Please sign in to post a comment.
Please use Updates for communications.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}